BDNF/TrkB activators in Parkinson's disease: A new therapeutic strategy

Journal of Cellular and Molecular Medicine, Journal Year: 2024, Volume and Issue: 28(10)

Published: May 1, 2024

Parkinson's disease (PD) is a neurodegenerative disorder of the brain and manifested by motor non-motor symptoms because degenerative changes in dopaminergic neurons substantia nigra. PD neuropathology associated with mitochondrial dysfunction, oxidative damage apoptosis. Thus, modulation apoptosis growth factors could be novel boulevard management PD. Brain-derived neurotrophic factor (BDNF) its receptor tropomyosin kinase type B (TrkB) are chiefly involved neuropathology. BDNF promotes survival nigra enhances functional activity striatal neurons. Deficiency TrkB triggers degeneration accumulation α-Syn As well, BDNF/TrkB signalling reduced early phase Targeting specific activators may attenuate this review aimed to discuss potential role against In conclusion, decreased linked severity long-term complications. Activation

Language: Английский

---

The Molecular Pathway of p75 Neurotrophin Receptor (p75NTR) in Parkinson’s Disease: The Way of New Inroads

Molecular Neurobiology, Journal Year: 2023, Volume and Issue: 61(5), P. 2469 - 2480

Published: Oct. 28, 2023

Language: Английский

---

The conceivable role of prolactin hormone in Parkinson disease: The same goal but with different ways

Ageing Research Reviews, Journal Year: 2023, Volume and Issue: 91, P. 102075 - 102075

Published: Sept. 14, 2023

Language: Английский

---

Parkinson’s Disease and Photobiomodulation: Potential for Treatment

Journal of Personalized Medicine, Journal Year: 2024, Volume and Issue: 14(1), P. 112 - 112

Published: Jan. 19, 2024

Parkinson’s disease is the second most common neurodegenerative and increasing in incidence. The combination of motor non-motor symptoms makes this a devastating for people with their care givers. characterised by mitochondrial dysfunction neuronal death substantia nigra, reduction dopamine, accumulation α-synuclein aggregates neuroinflammation. microbiome–gut–brain axis also important disease, involved spread inflammation aggregated α-synuclein. mainstay treatment dopamine replacement therapy, which can reduce some signs. There need additional options to supplement available medications. Photobiomodulation (PBM) form light therapy that has been shown have multiple clinical benefits due its enhancement electron transport chain subsequent increase membrane potential ATP production. PBM modulates cellular signalling inflammation. Clinically, used decades improve wound healing, treat pain, swelling heal deep tissues. Pre-clinical experiments indicated signs provide neuroprotection. This effect seen whether directed head animal or other parts body (remotely). A small number trials given weight possibility using both may potentially slow progression.

Language: Английский

---

The classical and non-classical axes of renin-angiotensin system in Parkinson disease: The bright and dark side of the moon

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 94, P. 102200 - 102200

Published: Jan. 17, 2024

Language: Английский

---

From Brain to Muscle: The Role of Muscle Tissue in Neurodegenerative Disorders

Biology, Journal Year: 2024, Volume and Issue: 13(9), P. 719 - 719

Published: Sept. 12, 2024

Neurodegenerative diseases (NDs), like amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and Parkinson's (PD), primarily affect the central nervous system, leading to progressive neuronal loss motor cognitive dysfunction. However, recent studies have revealed that muscle tissue also plays a significant role in these diseases. ALS is characterized by severe wasting as result of neuron degeneration, well alterations gene expression, protein aggregation, oxidative stress. Muscle atrophy mitochondrial dysfunction are observed AD, which may exacerbate decline due systemic metabolic dysregulation. PD patients exhibit fiber atrophy, altered composition, α-synuclein aggregation within cells, contributing symptoms progression. Systemic inflammation impaired degradation pathways common among disorders, highlighting key player Understanding muscle-related changes offers potential therapeutic avenues, such targeting function, reducing inflammation, promoting regeneration with exercise pharmacological interventions. This review emphasizes importance considering an integrative approach neurodegenerative research, both peripheral pathological mechanisms, order develop more effective treatments improve patient outcomes.

Language: Английский

---

Peripherally administered TNF inhibitor is not protective against α-synuclein-induced dopaminergic neuronal death in rats

Neurobiology of Disease, Journal Year: 2025, Volume and Issue: unknown, P. 106803 - 106803

Published: Jan. 1, 2025

The underlying cause of neuronal loss in Parkinson's disease (PD) remains unknown, but evidence implicates neuroinflammation PD pathobiology. pro-inflammatory cytokine soluble tumor necrosis factor (TNF) seems to play an important role and thus has been proposed as a therapeutic target for modulation the neuroinflammatory processes PD. In this regard, dominant-negative TNF (DN-TNF) agents are promising antagonists that selectively inhibit signaling, while preserving beneficial effects transmembrane TNF. Previous studies have tested protective potential DN-TNF-based therapy toxin-based models. Here we test first time DN-TNF against α-synuclein-driven neurodegeneration viral vector-based female rat model. To do so, administered agent XPro1595 subcutaneously period 12 weeks. contrast previous using different models, neuroprotection was not achieved by systemic treatment. α-synuclein-induced nigrostriatal neurons, accumulation pathological inclusions microgliosis detected both XPro1595- saline-treated animals. treatment increased percentage hypertrophic/ameboid Iba1+ cells SN reduced striatal MHCII+ expression α-synuclein-overexpressing However, did prevent MHCII upregulation seen model, nor increase CD68+ phagocytic cells. Therefore, despite apparently immunomodulatory effect, suffice protect vector-derived neurotoxicity. Further warranted better elucidate inhibitors

Language: Английский

---

Modification of bacterial cellulose by MoBTx MBene and 1,4-dithiothreitol for rapid and efficient adsorption of indomethacin and losartan potassium

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: unknown, P. 140745 - 140745

Published: Feb. 1, 2025

Language: Английский

---

The potential role of cholesterol in Parkinson’s disease neuropathology: perpetrator or victim

Neurological Sciences, Journal Year: 2023, Volume and Issue: 44(11), P. 3781 - 3794

Published: July 10, 2023

Language: Английский

---

The potential role of brain renin‐angiotensin system in the neuropathology of Parkinson disease: Friend, foe or turncoat?

Journal of Cellular and Molecular Medicine, Journal Year: 2024, Volume and Issue: 28(12)

Published: June 1, 2024

Abstract Parkinson disease (PD) is one of the most common neurodegenerative diseases brain. Of note, brain renin‐angiotensin system (RAS) intricate in PD neuropathology through modulation oxidative stress, mitochondrial dysfunction and neuroinflammation. Therefore, RAS by angiotensin receptor blockers (ARBs) angiotensin‐converting enzyme inhibitors (ACEIs) may be effective reducing risk neuropathology. It has been shown that all components including peptides enzymes are present different areas. Brain plays a critical role regulation memory cognitive function, controlling central blood pressure. However, exaggerated implicated pathogenesis PD. Two well‐known pathways recognized including; classical pathway which mainly mediated AngII/AT1R detrimental effects. Conversely, non‐classical mostly ACE2/Ang1‐7/MASR AngII/AT2R beneficial effects against Exaggerated affects viability dopaminergic neurons. fundamental mechanism was not fully elucidated. Consequently, purpose this review to disclose mechanistic In addition, we try revise how ACEIs ARBs can developed for therapeutics

Language: Английский

---